2160.T) announced that its subsidiary, Gyre Therapeutics, submitted a New Drug Application (NDA) to">
Pulse News Wire translates Japanese corporate disclosures filed with the Tokyo Stock Exchange's TDNet system into clear, structured English for institutional investors, hedge funds, and asset managers. Every article on this page is derived directly from an official TDNet filing — including earnings reports, M&A announcements, share buybacks, dividend declarations, and governance changes. Japanese corporate governance is governed by the Companies Act and the Financial Instruments and Exchange Act; timely translation of these disclosures provides a material information advantage for cross-border investors monitoring Tokyo-listed equities.
This corporate disclosure from GNI Group Ltd. was processed by Pulse News Wire on March 24, 2026. It represents a primary source document for Japanese Corporate sector intelligence, translated directly from an official filing submitted to the Tokyo Stock Exchange TDNet system.
TOKYO, Mar 24 (Pulse News Wire) – GNI Group Ltd. (2160.T) announced that its subsidiary, Gyre Therapeutics, submitted a New Drug Application (NDA) to China's National Medical Products Administration (